Fosun Pharma: Holding Subsidiary's Drug Registration Application Accepted

Fosun Pharma announced that its holding subsidiary, Fosun Kite Biotechnology Co., Ltd., has had its registration application for the drug Brexucabulin injection accepted by the National Medical Products Administration. The indication is for the treatment of relapsed or refractory precursor B cell acute lymphoblastic leukemia in adult patients. As of August 2025, the cumulative research and development investment in this product by the group is approximately 183 million RMB.